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In Europe, most reported human cases of babesiosis
have been attributed, without strong molecular evidence, to
infection with the bovine parasite Babesia divergens. We
investigated the first known human cases of babesiosis in
Italy and Austria, which occurred in two asplenic men. The
complete 18S ribosomal RNA (18S rRNA) gene was ampli-
fied from specimens of their whole blood by polymerase
chain reaction (PCR). With phylogenetic analysis, we com-
pared the DNA sequences of the PCR products with those
for other Babesia spp. The DNA sequences were identical
for the organism from the two patients. In phylogenetic
analysis, the organism clusters with B. odocoilei, a parasite
of white-tailed deer; these two organisms form a sister
group with B. divergens. This evidence indicates the
patients were not infected with B. divergens but with an
organism with previously unreported molecular characteris-
tics for the 18S rRNA gene. 
B
abesiosis is a tick-borne zoonosis caused by
intraerythrocytic protozoa of the genus Babesia (1,2).
The world’s first well-documented human case of
babesiosis was a fatal case in 1956 in an asplenic man in
the former Yugoslavia (3). Since then, hundreds of human
cases of babesiosis have been reported in the United States,
approximately 30 cases have been reported in Europe
(4–7), and a few cases have been reported elsewhere. 
Most of the reported U.S. cases have been caused by
infection with Babesia microti, a parasite of small mammals
transmitted by Ixodes scapularis ticks. Most European
cases have been attributed to B. divergens, a parasite of
cattle transmitted by I. ricinus. However, from 1991
through 2000, additional zoonotic Babesia and Babesia-like
pathogens have been identified and characterized with
molecular techniques. These pathogens include, in the
United States, the WA1- (for “Washington 1”) and CA1-
(for “California 1”) type parasites and the MO1 (for
“Missouri 1”) parasite (8–10) and, in Europe, the organism
we describe here. 
We report what to our knowledge are the first described
human cases of babesiosis in Italy and Austria and provide
evidence that the etiologic agent of the two cases, which is
related to but clearly not B. divergens, has molecular
characteristics that have not previously been reported.
Following the precedent we previously established for
reports of newly characterized organisms in the United
States, we refer here to this organism from Europe as EU1
(for “European Union 1”).
Methods
Serologic Testing
Serum specimens from the patients were tested at the
Centers for Disease Control and Prevention (CDC) in
serial fourfold dilutions by indirect fluorescent antibody
(IFA) testing for reactivity to B. microti (11), WA1 (8), and
B. divergens antigens. The antigen sources were human
isolates of B. microti and WA1 and a bovine isolate of B.
divergens (the Purnell strain from the Republic of Ireland
[12]) that had been passaged in gerbils (Mongolian jirds;
Meriones unguiculatus) and adapted to culture in bovine
erythrocytes. The serum specimens were also tested at the
Clinical Institute of Hygiene of the University of Vienna
by IFA for reactivity to B. divergens antigens (from a
bovine isolate from Hanover, Germany, that had been
passaged in jirds); the dilutions of serum that were tested
were 1:16, 1:64, 1:256, 1:1,000, and 1:4,000.
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Five jirds, which are competent hosts for B. divergens
(13), were injected intraperitoneally with 0.5 mL of 1-day
old, refrigerated, pretreatment blood from the Austrian
patient. Animal experimentation guidelines were followed.
The jirds were monitored periodically (at least weekly; 26
times in 17.5 weeks) for parasitemia by examination of
Diff Quik-stained (DADE AG, Düdingen, Switzerland)
smears of blood obtained either by tail snip or, at the end
of the monitoring period, by cardiac puncture after
anesthesia with ketamine. The blood obtained by cardiac
puncture was also examined by polymerase chain reaction
(PCR) (see below). 
DNA Extraction, Amplification, and Sequencing
DNAwas extracted from EDTA-stabilized whole blood
from the two patients by using the QIAamp DNA Blood
Mini Kit (QIAGEN Inc., Valencia, CA); the DNA was
stored at 4°C. The complete 18S ribosomal RNA (18S
rRNA) gene was amplified by PCR, with a pair of generic
apicomplexan 18S rRNA-specific primers: CRYPTOF, the
forward primer (5′-AACCTGGTTGATCCTGCCAGT-3′),
and CRYPTOR, the reverse primer (5′-GCTTGATC-
CTTCTGCAGGTTCACCTAC-3′). PCR was conducted
with the AmpliTaq Gold DNA Polymerase (Applied
Biosystems, Foster City, CA). The conditions for PCR
included 95°C for 15 min, followed by 45 cycles of
denaturation at 94°C for 30 s, annealing at 65°C for 30 s,
and extension at 72°C for 1.5 min. Final extension was
done at 72°C for 9 min, followed by a hold step at 4°C.
Amplification products were purified by using the
StrataPrep DNA Purification Kit (Stratagene, La Jolla,
CA). In addition, DNAprovided us that had been extracted
from two isolates of B. odocoilei (i.e., the Brushy Creek
and Engeling isolates [14]), a parasite of white-tailed deer
(Odocoileus virginianus) (15,16), and from B. divergens
(Purnell strain [12]) was analyzed. 
Both strands of the PCR products were sequenced by
using a set of internal primers. Sequencing reactions were
conducted with the ABI PRISM BigDye Terminator Cycle
Sequencing Kit (Applied Biosystems), and reactions were
analyzed on the ABI 377 or ABI 3100 automatic DNA
sequencer (Applied Biosystems). The resulting sequences
were assembled by using the program SeqMan II
(DNASTAR, Inc., Madison, WI). The GenBank accession
numbers for the complete sequences we generated of the
18S rRNA gene for the various organisms are as follows:
B. odocoilei, AY046577; B. divergens, AY046576; and
EU1, AY046575.
Phylogenetic Analysis
The complete sequences of the 18S rRNA genes for B.
bigemina, B. bovis, B. caballi, B. divergens, B. gibsoni, B.
odocoilei, and Babesia sp. (isolated from Bos taurus) were
retrieved from the GenBank database (see Figure 1 legend
for GenBank accession numbers) and aligned with the
sequence for EU1 by using the program CLUSTAL W
version 1.83 (17). The 18S rRNA sequence for Theileria
annulata was included as the outgroup for the
phylogenetic analysis. This analysis was performed with
the following programs: the PHYLIP package, which
includes version 3.573c of CONSENSE, DNADIST,
DNAML, NEIGHBOR, and SEQBOOT (18); and version
5.1 of TREE-PUZZLE (19). The phylogenetic trees
inferred by these programs were drawn by using the
program TreeView, version 1.6.6 (20). The trees were
statistically evaluated by using bootstrap (18) and quartet
puzzling methods (19). 
Case Reports
The Italian and Austrian patients were 55- and 56-year-
old men, respectively, who had undergone splenectomy in
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Figure 1. Phylogenetic tree for the complete 18S rRNA gene from
selected Babesia spp. The tree was computed by using the quar-
tet puzzling maximum likelihood method of the TREE-PUZZLE
program and was oriented by using Theileria annulata as the out-
group. Numbers at the nodes indicate the quartet puzzling support
for each internal branch. Scale bar indicates an evolutionary dis-
tance of 0.01 nucleotides per position in the sequence. Vertical
distances are for clarity only. The GenBank accession numbers for
the sequences used in the analysis are as follows: Babesia bigem-
ina A, X59604; B. bovis, L19077; B. caballi, Z15104; B. divergens
(Purnell isolate [12]), AY046576; B. gibsoni (genotype Asia 1),
AF175300; B. odocoilei (Brushy Creek and Engeling isolates [14]),
AY046577; Babesia sp. (isolated from Bos taurus), U09834; EU1
(the etiologic agent of infection in the two cases described here),
AY046575; and Theileria annulata, M64243.the 1980s because of stage IA Hodgkin’s disease. The
Italian patient had recently begun chemotherapy (Table
footnote) for stage IIIA diffuse large B-cell lymphoma,
which had been diagnosed in June 1998. Both men lived in
small towns and hunted avocationally (Table); neither had
pets. Only the Austrian patient recalled tick exposure—a
tick bite while hunting about 2 weeks before he noticed his
urine was dark. Neither patient had traveled extensively:
the Italian patient had never left Italy, and the Austrian
patient had been in Barbados (1998) and Turkey (1999).
The two cases ranged in severity from quite mild
(Austrian case) to moderately severe (Italian case). The
salient clinical details of their cases and the relevant
laboratory values are provided in the Table. Fever occurred
only in the Italian patient (maximum of 39°C), which
initially was considered a reaction to one of his
chemotherapeutic agents (i.e., bleomycin). He also had
marked anemia, for which he received blood transfusions
(Table). Both patients had thrombocytopenia, elevated
serum lactate dehydrogenase and bilirubin values, and
dark urine from hemoglobinuria. The Italian patient’s
creatinine value also was elevated.
In both cases, babesiosis was diagnosed by noting
parasitic inclusions in erythrocytes on peripheral blood
smears (Table; Figure 2). The intervals between onset of
the symptoms that ultimately were attributed to babesiosis
and confirmation of the diagnosis ranged from 2 days
(Austrian case) to 10 days (Italian case). Subsequent
testing of serum specimens from both patients showed IFA
reactivity to B. divergens but not to B. microti antigens;
serum from the Italian patient was also tested for reactivity
to WA1 antigens and was negative. Attempts to obtain an
isolate of the parasite that infected the Austrian patient, by
injecting specimens of his blood into jirds, were
unsuccessful; the smears of blood from periodic tail snips
and PCR analysis of blood obtained by cardiac puncture of
the jirds were negative. Both patients responded to
antimicrobial therapy for babesiosis: the Austrian patient
was treated with clindamycin, and the Italian patient was
treated with both clindamycin and quinine (Table). 
Molecular Data
Amplification of the complete 18S rRNA gene, by
using generic protozoan primers and the Babesia DNA
extracted from the patients as the templates, yielded a
specific product of approximately 1,700 base pairs for
each patient. Sequence analysis showed that the 18S rRNA
gene was 1,727 bases long and that the PCR products from
the two patients had identical sequences. BLAST
(available from: URL: http://www.ncbi.nlm.nih.gov/
BLAST/) search showed that the sequence, although
clearly from a Babesia sp., was not identical to any
complete 18S rRNA sequences in the GenBank database.
In phylogenetic analysis, EU1 clusters together with B.
odocoilei, and these two organisms form a sister group
with  B. divergens (Figure 1). The clustering of these
organisms was identical, regardless of which phylogenetic
method was used. The associations were strongly
supported statistically. Support for the internal branch
leading to the B. divergens, B. odocoilei, and EU1 group
was 100% with both quartet puzzling and bootstrapped
distance analysis; for the internal branch separating B.
divergens from  B. odocoilei and EU1, the support was
100% for quartet puzzling and 88% for bootstrapped
distance analysis. The alignment of the sequences used to
construct the phylogenetic tree (Figure 1) is available from
the authors upon request.
Because the complete 18S rRNA sequences in
GenBank that were previously determined for various
bovine isolates of B. divergens were not identical, we
reanalyzed the complete 18S rRNA gene from isolates
(cultures or DNA) from Ireland (Purnell [12]; GenBank
accession no. U16370), Germany (U07885 [21]), and
Northern Ireland (Z48751) that were provided to us. The
sequences of the 18S rRNA gene we obtained for these
isolates were identical, which suggests that no variability
is present in this gene among geographically distinct
bovine isolates of B. divergens (Slemenda et al., unpub.
data). In contrast, the EU1 and B. divergens 18S rRNA
sequences differed by 31 bases. 
Similarly, our sequences of the 18S rRNA gene for
both isolates of B. odocoilei (i.e., Brushy Creek and
Engeling isolates) were identical to each other (GenBank
accession no. AY046577) and to the B. odocoilei sequence
with the GenBank accession no. U16369 (14). The EU1
and B. odocoilei 18S rRNAsequences differed by 29 bases. 
Discussion
We investigated the first reported human cases of
babesiosis in Italy and Austria and have provided
molecular evidence that the etiologic agent was a
previously uncharacterized Babesia organism, which we
refer to here as EU1. The organism was found in countries
in Europe not previously known to have zoonotic
babesiosis and had novel molecular characteristics for the
genetic marker we analyzed, the complete 18S rRNAgene.
Sequence analysis of this gene provides an objective and
precise means of species identification and phylogenetic
classification. The DNA sequences of the 18S rRNA gene
were identical for the Babesia organisms from the two
patients, which indicates that they were infected with the
same organism. Each of the organisms was sequenced in a
different country, which indicates that the findings were
not artifactual. 
The phylogenetic analysis (Figure 1) indicates that
EU1 is most closely related to but distinct from B.
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Table. Characteristics of two men who had babesiosis in 1998 and 2000, respectively  
Characteristics  Italian patient
b,c  Austrian patient 
Residence and outdoor activities   Lived in northern Italy, in a small town in 
the district of Romagna, on ~1 hectare of 
land; often hunted moles in his garden, even 
after he started chemotherapy  
Lived in northeastern Austria, in a small town in 
the district of Krems Land, in the province of 
Lower Austria; had an off-site garden; often 
hunted in the Dunkelsteinerwald forest (usually 
wild boars, sometimes foxes and badgers) 
Clinical illness and general laboratory data     
Initial clinical manifestations  Fever (39EC) and chills developed on 
October 14, 1998; hospitalized on October 
18 because of fever, headache, confusion, 
jaundice, and dark urine (discharged on 
November 6)  
Marked fatigue developed on July 23, 2000; 
dark urine, without dysuria, developed on July 
24; hospitalized on July 25 (discharged on 
August 2) 
Hematologic parameters
d     
Hemoglobin (g/dL)  4.8  15
e (13.2 on July 27, 2000) 
Leukocyte count (x10
9/L)  4.4  7.3 (7.8, with 5% atypical lymphocytes,  
on July 26) 
Platelet count (x10
9/L)  71  15 (8 on July 27) 
Values of serum chemistries
d     
Lactate dehydrogenase (U/L)  7,877 (normal range 230–460)  994 (July 26, 2000) (normal range 120–240) 
Total bilirubin (mg/dL)  3.2 (normal range 0.2–1.10)  3.27 (July 26) (normal range 0.2–1.0) 
Indirect bilirubin (mg/dL)  2.4 (normal range 0.2–0.85)  2.36 (July 26) (normal range 0.0–1.0) 
Direct (conjugated) bilirubin (mg/dL)  0.8 (normal range 0.0–0.25)  0.91 (July 26) (normal range 0.0–0.25) 
Creatinine (mg/dL)  2.5 (normal range 0.50–1.20)  1.04 (normal range 0.5–1.3) 
Diagnosis of Babesia infection     
Parasitemia level (% of erythrocytes that were 
infected) on first blood smear examined 
~30% (October 24, 1998)  1.3% (July 25, 2000) (Figure 2) 
Antibody titers in IFA testing for reactivity to 
B. divergens antigens
f 
Titers of 1:64 (specimen from October 28, 
1998) and 1:256 (February 15, 1999) in 
testing at both CDC and the Clinical 
Institute of Hygiene of the University of 
Vienna 
Titers of 1:256 (July 31, 2000) and 1:1,024 
(August 8, 2000) in testing at CDC and titers of 
1:64 (July 31) and 1:1,000 (August 8) in testing 
at the Clinical Institute of Hygiene of the 
University of Vienna 
Therapy for babesiosis     
Antimicrobial therapy  Clindamycin (600 mg thrice daily, by 
intravenous infusion) and quinine sulfate 
(650 mg thrice daily, by mouth) for 15 days, 
from October 24, 2000 (i.e., 10 days after 
onset of fever), through November 7 
Clindamycin (600 mg thrice daily), by 
intravenous infusion, for 8 days, from  July 25, 
2000 (i.e., 2 days after onset of symptoms), 
through August 1, and by mouth, for 15 days 
thereafter (through August 15) 
Blood transfusions  11 U packed erythrocytes, from October 
19–31, 1998
c,g 
None 
Response to therapy  Fever resolved by day 3 of therapy; no 
parasites found by blood-smear examination 
after day 6 of therapy; negative PCR 
analysis of blood from February 15, 1999 
Blood from August 8, 2000, negative by blood-
smear examination but positive by PCR 
analysis; negative PCR analysis of blood from 
November 7, 2000, and February 8, 2001 
Long-term follow-up  Non-Hodgkin’s lymphoma remitted during 
hospitalization in 1998, but the lymphoma 
relapsed in February 2000; no parasites 
were found on blood smears during 
subsequent chemotherapy 
Remained well  
aIFA, indirect fluorescent antibody; PCR, polymerase chain reaction; CDC, Centers for Disease Control and Prevention.  
bNon-Hodgkin’s lymphoma developed in the Italian patient (diagnosis: June 1998). Chemotherapy, begun on September 23, 1998, was stopped prematurely on October 
14, after he became febrile. His chemotherapeutic regimen included daily prednisone (75 mg) and weekly administration of various drugs in rotation. He received 4 of 
the intended 12 weeks of therapy, which included doxorubicin and cyclophosphamide during odd-numbered weeks (weeks 1 and 3) and vincristine and either 
methotrexate (week 2) or bleomycin (week 4) during even-numbered weeks.  
cAlthough the possibility that he became infected by blood transfusion could not be excluded because he had been transfused before blood smears were examined, his 
febrile illness and hemolytic anemia preceded the transfusions.  
dLaboratory values were from hospital admission (October 18, 1998, for the Italian patient, and July 25, 2000, for the Austrian patient), unless otherwise specified. 
Values for the Austrian patient are from testing performed at the hospital to which he was transferred after a brief (<24-hour) stay at a local hospital.  
eEarlier on July 25, at a local hospital, his hemoglobin value was 16.2 g/dL, which had been his approximate baseline value during the previous 10 months.  
fIFA testing of serum specimens from both patients was negative for antibodies to B. microti. A specimen from the Italian patient (February 15, 1999) was negative for 
antibodies to WA1.  
gPlasma exchange was performed on October 23, when he mistakenly was thought to have thrombotic thrombocytopenic purpura. 
odocoilei, which infects white-tailed deer (15,16) and is
not known to infect humans. EU1 and B. odocoilei form a
sister group to B. divergens, a bovine parasite that has been
considered the main Babesia pathogen of humans in
Europe. We have demonstrated that no variability exists in
the 18S rRNA sequences among several geographically
distinct bovine isolates of B. divergens (Slemenda et al.,
unpub. data), which is the organism to which the name B.
divergens legitimately applies, and showed that EU1
clearly is not B. divergens. 
EU1 is also distinct from the MO1 parasite, which
caused a fatal human case of babesiosis in Missouri in
a1992 and was thought then by the investigators to be B.
divergens–like but distinct from it (10). The sequence
provided in the publication about MO1 (10) was for only a
128–base pair fragment; in that region, the EU1 and MO1
sequences differ by four bases, and three positions in the
MO1 sequence were unresolved. 
The DNA sequences available in GenBank for B.
divergens in Europe are from cattle not humans. To our
knowledge, molecular data have been reported for only
one of the purported human cases of B. divergens infection
in Europe, a case on the Canary Islands (22,23). However,
the data were for an incomplete 18S rRNA sequence
(GenBank accession no. AF435415), and therefore were
not suitable for the phylogenetic analysis we performed of
complete 18S rRNA sequences. Nevertheless, the
sequence for the case on the Canary Islands differs by 18
bases with the sequence for EU1 and by 1 base with the B.
divergens sequence from cattle (AY046576) in the 369-
base-long region of the gene that could be compared. 
In the absence of molecular data, we are not certain
which organisms have caused the human cases of
babesiosis in Europe that have been attributed to B.
divergens. The evidence that particular human cases were
caused by B. divergens has varied in quantity, quality, and
type. The evidence typically has included various
combinations of morphologic data, from examination of
blood smears; serologic data (usually, but not always, from
IFA testing); and data concerning whether jirds or cattle
injected with the patient’s blood become parasitemic.
Although these techniques are useful for detecting Babesia
infection, they do not necessarily provide reliable species
identification (e.g., because of serologic cross-reactivity
between EU1 and B. divergens in IFA testing [Table]).
Although some of the human cases attributed to B.
divergens may truly have been caused by the bovine B.
divergens, others might have been caused by EU1. The
cases of EU1 infection we reported likely would have been
attributed to B. divergens had only the traditional methods
of characterization, without molecular analysis, been used. 
Our molecular characterization also showed that EU1
is not closely related to the other Babesia (or Babesia-like)
agents known to have infected humans (most notably, B.
microti and the WA1- and CA1-type parasites). B. microti,
together with B. rodhaini, Cytauxzoon felis, and B. equi, is
ancestral to the Theileria spp. and perhaps also to the
Babesia  sensu stricto group (depending on which tree
topology is used) (24). Reclassification of the B. microti
group to a new family has been proposed (24). The WA1-
and CA1-type parasites, which have caused human cases
of babesiosis in the western United States (8,9), also form
a well-defined group, whose position in the phylogeny of
the piroplasms is uncertain (25).
Although EU1 represents a zoonotic pathogen with
previously unreported molecular characteristics, whether it
represents a new species per se awaits further evidence.1
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Figure 2. Panel of computer-generated elec-
tronic images of photomicrographs of
Babesia-infected erythrocytes on a Giemsa-
stained smear of peripheral blood from the
patient who became infected in Austria. The
electronic images were edited for uniformity
of color, without changing the form or size of
the organisms. The image on the bottom
shows a tetrad (Maltese-cross form). Three
glass slides of the actual blood films have
been deposited in the Oberösterreichisches
Landesmuseum, Biologiezentrum, Linz (i.e.,
Biology Center of the Upper Austrian
Museum, Linz), with the accession number
2002/9. The slides are labeled “Babesia sp.
(EU1), patient 001, Austria, Krems Land, July
25, 2000.” 
1The issue of what constitutes a new or newly described species requires
periodic reevaluation as the techniques for characterizing microbes
improve. Although the advent of molecular biology/phylogeny has made it
possible to characterize organisms more precisely, the issue of how large a
genetic difference in a particular gene(s) constitutes a new or different
species is controversial. Bacterial taxonomy is a much more active and
advanced field (26,27) than that for characterizing protozoa, in part because
of the increasingly large numbers of bacteria being proposed as new
species and the challenges posed by such possibilities as genetic
rearrangements. In the recommendations published in 2002 by an ad hoc
committee that reevaluated the species definition for bacteria (26), scientists
were encouraged to use the “Candidatus” concept (i.e., to propose candi-
dates for newly described bacterial species) for organisms that had been
well-characterized, including the sequencing of the small subunit RNAgene,
but had not yet been cultured. 
As noted above, we have referred to the protozoan we characterized as
EU1. We have not claimed it is a newly identified species, despite having
complete, identical, and novel 18S rRNA sequences for the organism from
two patients, who were separated in time and space, and having done the
sequence analysis for the two cases in different countries. However,
although the “Candidatus” concept per se does not formally exist now for
protozoa, on the basis of the precedent from the field of bacterial taxonomy,
we propose that EU1 be considered a candidate species. If additional evi-
dence supports the conclusion that the organism indeed constitutes a newly
described species of the Babesia genus, we would favor the name Babesia
venatorum, which now does not constitute an official name. We chose this
name because the patients whose cases we reported were avocational
hunters; “venator” is the Latin word for “hunter” (“venatorum,” the plural gen-
itive case, means “of the hunters”).EU1 might constitute a new species in the sense that it was
never previously recognized or characterized in any way or
one that was characterized but not with molecular data
(e.g., was misnamed B. divergens or some other Babesia
sp.). Because DNAsequence data are not available for most
of the Babesia spp. found over the past century in
nonhuman animals and because data about the morphologic
features and host specificity of a parasite are inadequate for
definitive species identification, we cannot exclude the
possibility that EU1 is one of the many previously
described Babesia spp. of nonhuman animals, some named
and some not, that were not known to be zoonotic.
Although the serologic cross-reactivity between EU1
and  B. divergens could have resulted in diagnostic
confusion in the past, cross-reactivity between these two
organisms also could be advantageous. The B. divergens
IFA could be a useful tool for testing serum from persons
who might be infected with EU1 or who participate in
serosurveys to determine the prevalence and geographic
distribution of EU1 infection. Unfortunately, our attempts
to obtain an isolate of EU1 by inoculation of jirds were
unsuccessful. One consequence is that we did not generate
the homologous antigen needed for development of an IFA
assay for EU1. Therefore, we could not contrast the degree
of reactivity of our patients’ serum specimens with
antigens from EU1 and B. divergens.
The importance of determining whether the etiologic
agent of a particular case of babesiosis is EU1 rather than
B. divergens or some other Babesia sp. depends in part on
whether the clinical manifestations of infection and the
response to antimicrobial therapy differ. We cannot
generalize about such issues from two cases of infection
with EU1. However, the range in severity of the two cases,
from quite mild (Austrian case) to moderately severe
(Italian case), is of interest, particularly because the two
patients were similar in some respects (i.e., both were
asplenic men in their mid-fifties). Factors that likely
placed the Italian patient at increased risk for a more
severe case included immunosuppressive chemotherapy
for lymphoma and the 10-day interval between the onset of
fever and the diagnosis of babesiosis (Table). 
Largely from data for B. microti infection in the United
States, combination therapy with either clindamycin and
quinine or atovaquone and azithromycin is recommended
for treatment of babesiosis (28), with the addition of
exchange transfusion in some situations in severely ill
patients. The Austrian patient, whose case was mild, was
treated with clindamycin only. Some in vitro data and
anecdotal clinical data for purported zoonotic cases of B.
divergens infection suggest that therapy with clindamycin
alone, in combination with exchange transfusion, when
indicated, might be effective for treating B. divergens
infection (4,29,30). However, no clinical trials in humans
have evaluated the effectiveness of any antimicrobial
regimens for treatment of Babesia infection not caused by
B. microti. 
The public health importance of infection with EU1,
including such factors as its biology, geographic
distribution, ecology, prevalence, risk factors for infection
and disease, clinical manifestations, tick vector, and
animal reservoir host(s), is not yet known and may take
years to determine. The Italian patient likely became
infected in a garden habitat and the Austrian patient in a
garden or forest habitat. Of interest, an incomplete 18S
rRNA sequence (GenBank accession no. AF373333) for a
Babesia sp. found in I. ricinus ticks was recently reported
by investigators in Slovenia (31), which borders Italy and
Austria. The sequence was reported for only 364 bases and
corresponds to positions 433–796 of the complete 18S
rRNA sequence for EU1. In this part of the gene, the
sequences for the organisms from the Slovenian ticks and
EU1 are identical. However, the relatedness of the two
organisms cannot be determined without the complete 18S
rRNA sequence for the organism from the ticks. The
occurrence of two identified cases of EU1 infection in
humans in different countries (i.e., Italy and Austria) and
years (i.e., 1998 and 2000) indicates that EU1 is not
restricted to one geographic area or time. Increased
vigilance for zoonotic infection with novel vector-borne
pathogens is needed. 
Acknowledgments
We thank Henry S. Bishop, Doris A. Ware, Patricia B.
Wilkins, and Marianna Wilson for laboratory support; Mark L.
Eberhard and James Maguire for helpful advice; Otto Picher, Sue
Dillard, and Dennis D. Juranek for help with Figure 2; Patricia
Holman for providing DNA extracted from two isolates of
Babesia odocoilei and one isolate of B. divergens; and Jeremy
Gray, Ute Mackenstedt, John Kenny, and Gale Wagner for pro-
viding bovine isolates (cultures or DNA) of B. divergens. 
This work was supported in part by the Italian Association
of Cancer Research (G.M.), Associazione Italiana contro le
Leucemie-Linfomi and ATENEO 60% target projects grants
(P.P.), and the Murst 40% (Cofin 2002 – Michele Baccarani)
project (F.G.). 
Dr. Herwaldt is a medical epidemiologist in the Parasitic
Diseases Epidemiology Branch, Division of Parasitic Diseases,
Centers for Disease Control and Prevention. Her research inter-
ests include the epidemiology of various protozoan parasites,
such as Babesia, Leishmania, Trypanosoma, and Cyclospora spp. 
References 
1. Kjemtrup AM, Conrad PA. Human babesiosis: an emerging tick-
borne disease. Int J Parasitol 2000;30:1323–37.
Emerging Infectious Diseases • Vol. 9, No. 8, August 2003 947
RESEARCH2. Homer MJ, Aguilar-Delfin I, Telford SR 3d, Krause PJ, Persing DH.
Babesiosis. Clin Microbiol Rev 2000;13:451–69. 
3. Škrabalo Z, Deanovic' Z. Piroplasmosis in man: report on a case.
Documenta de Medicina Geographica et Tropica 1957;9:11–6. 
4. Gorenflot A, Moubri K, Precigout E, Carcy B, Schetters TPM.
Human babesiosis. Ann Trop Med Parasitol 1998;92:489–501. 
5. Denes E, Rogez JP, Dardé ML, Weinbreck P. Management of Babesia
divergens babesiosis without a complete course of quinine treatment.
Eur J Clin Microbiol Infect Dis 1999;18:672–3.
6. López Jiménez L, Aramburo González P, Barbadillo García de
Velasco R, Dámaso D, Daza RM, Lucero Ocaña MJ, et al. Babesiosis
en un enfermo esplenectomizado. Evolucíon satisfactoria con
exanguinotransfusíon. Rev Esp Microbiol Clin 1986;1:121–2. 
7. Berry A, Morassin B, Kamar N, Magnaval J-F. Clinical picture:
human babesiosis. Lancet 2001;357:41.
8. Quick RE, Herwaldt BL, Thomford JW, Garrett ME, Eberhard ML,
Wilson M, et al. Babesiosis in Washington State: a new species of
Babesia? Ann Intern Med 1993;119:284–90.
9. Persing DH, Herwaldt BL, Glaser C, Lane RS, Thomford JW,
Mathiesen D, et al. Infection with a Babesia-like organism in
northern California. N Engl J Med 1995;332:298–303.
10. Herwaldt BL, Persing DH, Précigout EA, Goff WL, Mathiesen DA,
Taylor PW, et al. Afatal case of babesiosis in Missouri: identification
of another piroplasm that infects humans. Ann Intern Med
1996;124:643–50.
11. Chisholm ES, Ruebush TK 2d, Sulzer AJ, Healy GR. Babesia microti
infection in man: evaluation of an indirect immunofluorescent
antibody test. Am J Trop Med Hyg 1978;27(1 Pt 1):14–9. 
12. Purnell RE, Brocklesby DW, Hendry DJ, Young ER. Separation and
recombination of Babesia divergens and Ehrlichia phagocytophila
from a field case of redwater from Eire. Vet Rec 1976;99:415–7.
13. Lewis D, Williams H. Infection of the Mongolian gerbil with the
cattle piroplasm Babesia divergens. Nature 1979;278:170–1. 
14. Holman PJ, Madeley J, Craig TM, Allsopp BA, Allsopp MTEP,
Petrini KR, et al. Antigenic, phenotypic and molecular
characterization confirms Babesia odocoilei isolated from three
cervids. J Wildl Dis 2000;36:518–30.
15. Waldrup KA, Kocan AA, Qureshi T, Davis DS, Baggett D, Wagner
GG. Serological prevalence and isolation of Babesia odocoilei among
white-tailed deer (Odocoileus virginianus) in Texas and Oklahoma. J
Wildl Dis 1989;25:194–201.
16. Kocan AA, Kocan KM. Tick-transmitted protozoan diseases of
wildlife in North America. Bull Soc Vector Ecol 1991;16:94–108. 
17. Thompson JD, Higgins DG, Gibson TJ. CLUSTALW: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight
matrix choice. Nucleic Acids Res 1994;22:4673–80.
18. Felsenstein J. PHYLIP - Phylogeny inference package (version 3.2).
Cladistics 1989;5:164–6.
19. Strimmer K, von Haeseler A. Quartet puzzling: a quartet maximum-
likelihood method for reconstructing tree topologies. Mol Biol Evol
1996;13:964–9.
20. Page RDM. TreeView: an application to display phylogenetic trees on
personal computers. Computer Applications in the Biosciences
1996;12:357–8.
21. Mackenstedt U, Luton K, Baverstock PR, Johnson AM. Phylogenetic
relationships of Babesia divergens as determined from comparison of
small subunit ribosomal RNA gene sequences. Mol Biochem
Parasitol 1994;68:161–5.
22. Miguélez M. Babesiosis en un paciente esplenectomizado. ¿El primer
caso español? [Letter.] Med Clin (Barc) 1997;108:717. 
23. Olmeda AS, Armstrong PM, Rosenthal BM, Valladares B, del
Castillo A, de Armas F, et al. Asubtropical case of human babesiosis.
Acta Trop 1997;67:229–34.
24. Allsopp MTEP, Cavalier-Smith T, De Waal DT, Allsopp BA.
Phylogeny and evolution of the piroplasms. Parasitology
1994;108:147–52.
25. Kjemtrup AM, Thomford J, Robinson T, Conrad PA. Phylogenetic
relationships of human and wildlife piroplasm isolates in the western
United States inferred from the 18S nuclear small subunit RNAgene.
Parasitology 2000;120:487–93.
26. Stackebrandt E, Frederiksen W, Garrity GM, Grimont PAD, Kämpfer
P, Maiden CJ, et al. Report of the ad hoc committee for the re-evalu-
ation of the species definition in bacteriology. Int J Syst Evol
Microbiol 2002;52:1043–7.
27. Christensen H, Bisgaard M, Frederiksen W, Mutters R, Kuhnert P,
Olsen JE. Is characterization of a single isolate sufficient for valid
publication of a new genus or species? Proposal to modify
Recommendation 30b of the Bacteriological Code (1990 Revision).
Int J Syst Evol Microbiol 2001;51:2221–5.
28. Krause PJ, Lepore T, Sikand VK, Gadbaw J, Burke G, Telford SR 3d,
et al. Atovaquone and azithromycin for the treatment of babesiosis. N
Engl J Med 2000;343:1454–8.
29. Brasseur P, Lecoublet S, Kapel N, Favennec L, Ballet JJ. Quinine in
the treatment of Babesia divergens infections in humans. Eur J Clin
Microbiol Infect Dis 1996;15:840–1. 
30. Brasseur P, Lecoublet S, Kapel N, Favennec L, Ballet JJ. In vitro
evaluation of drug susceptibilities of Babesia divergens isolates.
Antimicrob Agents Chemother 1998;42:818–20.
31. Duh D, Petovec M, Avsic-Zupanc T. Diversity of Babesia infecting
European sheep ticks (Ixodes ricinus). J Clin Microbiol
2001;39:3395–7.
Address for correspondence: Barbara L. Herwaldt, Centers for Disease
Control and Prevention, Division of Parasitic Diseases, 1600 Clifton
Road NE, Mailstop F22, Atlanta, GA 30333, USA; fax: 770-488-7761;
email: bxh4@cdc.gov 
948 Emerging Infectious Diseases • Vol. 9, No. 8, August 2003
RESEARCH